Novel Amylin-Based Therapies for Weight Management in Adults With Overweight or Obesity Without Diabetes: A Network Meta-Analysis - PubMed
2 hours ago
- #amylin-based therapies
- #network meta-analysis
- #weight management
- High-dose subcutaneous amycretin showed the largest reduction in percent body weight (-23.95%), followed by high-dose eloralintide (-18.01%) and high-dose CagriSema (-17.18%).
- All high-dose amylin-based therapies surpassed weight loss outcomes of semaglutide 2.4 mg (-11.45%) and liraglutide 3.0 mg (-6.4%).
- Similar weight loss patterns were observed for absolute weight, BMI, waist circumference, and categorical weight-loss thresholds.
- High-dose amylin-based therapies increased gastrointestinal adverse events (nausea, vomiting, constipation), particularly with oral amycretin and CagriSema.
- Only high-dose CagriSema increased adverse event-related discontinuation rates.
- The findings are preliminary due to sparse, low-certainty data, requiring confirmation in larger trials.